Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine immunomodulation study in mild to moderate COVID-19
ChiCTR2200067174Phase 4Not yet recruiting
- Sponsor
- Fifth Hospital of Shijiazhuang City
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azvudine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fifth Hospital of Shijiazhuang City. Primary endpoints: Changes in immunocyte at 14 days and Changes in cytokine at 14 days. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200067174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067174.